Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients
Background Paclitaxel (PTX) is an essential anticancer drug used to treat breast cancer. Because it contains alcohol as a solvent, it is contraindicated in many Japanese breast cancer patients when they are suspected of alcohol intolerance. Aldehyde dehydrogenase 2 (ALDH2) is one of several enzymes...
Gespeichert in:
| Veröffentlicht in: | Breast cancer (Tokyo, Japan) Japan), 2019-03, Vol.26 (2), p.229-234 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 234 |
|---|---|
| container_issue | 2 |
| container_start_page | 229 |
| container_title | Breast cancer (Tokyo, Japan) |
| container_volume | 26 |
| creator | Yagi, Toshinari Fujiishi, Koto Hasegawa, Akiko Otsuka, Tomoyuki Yoshinami, Tetsuhiro Nishio, Minako Fujisawa, Fumie Sugimoto, Naotoshi Imamura, Fumio |
| description | Background
Paclitaxel (PTX) is an essential anticancer drug used to treat breast cancer. Because it contains alcohol as a solvent, it is contraindicated in many Japanese breast cancer patients when they are suspected of alcohol intolerance. Aldehyde dehydrogenase 2 (ALDH2) is one of several enzymes that catalyzes dehydrogenation of aldehydes, and plays an important role in ethanol metabolism. Deficiency of this isozyme is believed to be responsible for facial flushing and other unpleasant symptoms following ethanol intake. In this study, we examined the safety of PTX for patients with the ALDH2 GA genotype.
Methods
We performed ALDH2 genotyping on 25 patients with various cancers who were suspected to be intolerant to alcohol based on an interview using a simple question. Ten patients with the ALDH2 GA genotype, including 5 breast cancer patients, underwent chemotherapy containing PTX up to 100 mg/m
2
(range 80–100 mg/m
2
), and were questioned about 16 alcohol-related symptoms at 11 timepoints to evaluate sensitivity to alcohol.
Results
All patients completed the first course of planned chemotherapy with either no or grade 1 alcohol-related symptoms.
Conclusions
Our study suggests that PTX up to 100 mg/m
2
can be used safely for patients with the ALDH2 GA genotype. To confirm the necessity of a genotyping test for ALDH2, further studies evaluating alcohol sensitivity in response to PTX among patients with the ALDH2 AA genotype are required. |
| doi_str_mv | 10.1007/s12282-018-0918-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179226813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712280456</galeid><sourcerecordid>A712280456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-93a1aa68286cfbae01c253cd35c8c63074668c0dda2d1b7167585e952316a9303</originalsourceid><addsrcrecordid>eNp9kcuKFTEQhoMozkUfwI00uHHTYy7d6fTyMIw3BtzoOlQn1Wcy5CRtkoNz3t60PQqCSCBVSb6_qNRPyCtGrxilw7vMOFe8pUy1dKzb-IScM6Vo23EhntZcdLSVSqozcpHzPaWdGKh8Ts4EFT3l_XhOfuy8xbuTxeZXSHGPATI2vKlJLKcFGxeaEj0mmJx35dTEuQFv4l30jYmhgAtoV2gBU9_hAf16-gwLBKyVpoSQS2MgGEwVKg5DyS_Isxl8xpeP8ZJ8e3_z9fpje_vlw6fr3W1rOtGXdhTAAKTiSpp5AqTM8F4YK3qjjBR06KRUhloL3LJpYHLoVY9jzwWTMNZvXpK3W90lxe9HzEUfXDbofW0uHrPmbBg5l4qJir7Z0D141C7MsSQwK653wzpp2vWyUlf_oOqyeHB1Hji7ev-XgG0Ck2LOCWe9JHeAdNKM6tVGvdmoq416tVGPVfP6sevjdED7R_HbtwrwDcj1Kewx6ft4TKFO8j9VfwLBaqdW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179226813</pqid></control><display><type>article</type><title>Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Yagi, Toshinari ; Fujiishi, Koto ; Hasegawa, Akiko ; Otsuka, Tomoyuki ; Yoshinami, Tetsuhiro ; Nishio, Minako ; Fujisawa, Fumie ; Sugimoto, Naotoshi ; Imamura, Fumio</creator><creatorcontrib>Yagi, Toshinari ; Fujiishi, Koto ; Hasegawa, Akiko ; Otsuka, Tomoyuki ; Yoshinami, Tetsuhiro ; Nishio, Minako ; Fujisawa, Fumie ; Sugimoto, Naotoshi ; Imamura, Fumio</creatorcontrib><description>Background
Paclitaxel (PTX) is an essential anticancer drug used to treat breast cancer. Because it contains alcohol as a solvent, it is contraindicated in many Japanese breast cancer patients when they are suspected of alcohol intolerance. Aldehyde dehydrogenase 2 (ALDH2) is one of several enzymes that catalyzes dehydrogenation of aldehydes, and plays an important role in ethanol metabolism. Deficiency of this isozyme is believed to be responsible for facial flushing and other unpleasant symptoms following ethanol intake. In this study, we examined the safety of PTX for patients with the ALDH2 GA genotype.
Methods
We performed ALDH2 genotyping on 25 patients with various cancers who were suspected to be intolerant to alcohol based on an interview using a simple question. Ten patients with the ALDH2 GA genotype, including 5 breast cancer patients, underwent chemotherapy containing PTX up to 100 mg/m
2
(range 80–100 mg/m
2
), and were questioned about 16 alcohol-related symptoms at 11 timepoints to evaluate sensitivity to alcohol.
Results
All patients completed the first course of planned chemotherapy with either no or grade 1 alcohol-related symptoms.
Conclusions
Our study suggests that PTX up to 100 mg/m
2
can be used safely for patients with the ALDH2 GA genotype. To confirm the necessity of a genotyping test for ALDH2, further studies evaluating alcohol sensitivity in response to PTX among patients with the ALDH2 AA genotype are required.</description><identifier>ISSN: 1340-6868</identifier><identifier>ISSN: 1880-4233</identifier><identifier>EISSN: 1880-4233</identifier><identifier>DOI: 10.1007/s12282-018-0918-9</identifier><identifier>PMID: 30350259</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Aldehyde Dehydrogenase, Mitochondrial - genetics ; Aldehydes ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - chemistry ; Asian People - genetics ; Breast cancer ; Breast Neoplasms - genetics ; Breath Tests ; Cancer ; Cancer patients ; Cancer Research ; Care and treatment ; Chemotherapy ; Dehydrogenation ; Enzymes ; Ethanol - adverse effects ; Ethanol - analysis ; Female ; Genetic aspects ; Humans ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasms - drug therapy ; Neoplasms - genetics ; Oncology ; Original Article ; Paclitaxel - adverse effects ; Paclitaxel - chemistry ; Paclitaxel - therapeutic use ; Physiological aspects ; Surgery ; Surgical Oncology</subject><ispartof>Breast cancer (Tokyo, Japan), 2019-03, Vol.26 (2), p.229-234</ispartof><rights>The Japanese Breast Cancer Society 2018</rights><rights>COPYRIGHT 2019 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-93a1aa68286cfbae01c253cd35c8c63074668c0dda2d1b7167585e952316a9303</citedby><cites>FETCH-LOGICAL-c435t-93a1aa68286cfbae01c253cd35c8c63074668c0dda2d1b7167585e952316a9303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12282-018-0918-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12282-018-0918-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30350259$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yagi, Toshinari</creatorcontrib><creatorcontrib>Fujiishi, Koto</creatorcontrib><creatorcontrib>Hasegawa, Akiko</creatorcontrib><creatorcontrib>Otsuka, Tomoyuki</creatorcontrib><creatorcontrib>Yoshinami, Tetsuhiro</creatorcontrib><creatorcontrib>Nishio, Minako</creatorcontrib><creatorcontrib>Fujisawa, Fumie</creatorcontrib><creatorcontrib>Sugimoto, Naotoshi</creatorcontrib><creatorcontrib>Imamura, Fumio</creatorcontrib><title>Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients</title><title>Breast cancer (Tokyo, Japan)</title><addtitle>Breast Cancer</addtitle><addtitle>Breast Cancer</addtitle><description>Background
Paclitaxel (PTX) is an essential anticancer drug used to treat breast cancer. Because it contains alcohol as a solvent, it is contraindicated in many Japanese breast cancer patients when they are suspected of alcohol intolerance. Aldehyde dehydrogenase 2 (ALDH2) is one of several enzymes that catalyzes dehydrogenation of aldehydes, and plays an important role in ethanol metabolism. Deficiency of this isozyme is believed to be responsible for facial flushing and other unpleasant symptoms following ethanol intake. In this study, we examined the safety of PTX for patients with the ALDH2 GA genotype.
Methods
We performed ALDH2 genotyping on 25 patients with various cancers who were suspected to be intolerant to alcohol based on an interview using a simple question. Ten patients with the ALDH2 GA genotype, including 5 breast cancer patients, underwent chemotherapy containing PTX up to 100 mg/m
2
(range 80–100 mg/m
2
), and were questioned about 16 alcohol-related symptoms at 11 timepoints to evaluate sensitivity to alcohol.
Results
All patients completed the first course of planned chemotherapy with either no or grade 1 alcohol-related symptoms.
Conclusions
Our study suggests that PTX up to 100 mg/m
2
can be used safely for patients with the ALDH2 GA genotype. To confirm the necessity of a genotyping test for ALDH2, further studies evaluating alcohol sensitivity in response to PTX among patients with the ALDH2 AA genotype are required.</description><subject>Adult</subject><subject>Aged</subject><subject>Aldehyde Dehydrogenase, Mitochondrial - genetics</subject><subject>Aldehydes</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Asian People - genetics</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breath Tests</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Dehydrogenation</subject><subject>Enzymes</subject><subject>Ethanol - adverse effects</subject><subject>Ethanol - analysis</subject><subject>Female</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - genetics</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Paclitaxel - adverse effects</subject><subject>Paclitaxel - chemistry</subject><subject>Paclitaxel - therapeutic use</subject><subject>Physiological aspects</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><issn>1340-6868</issn><issn>1880-4233</issn><issn>1880-4233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcuKFTEQhoMozkUfwI00uHHTYy7d6fTyMIw3BtzoOlQn1Wcy5CRtkoNz3t60PQqCSCBVSb6_qNRPyCtGrxilw7vMOFe8pUy1dKzb-IScM6Vo23EhntZcdLSVSqozcpHzPaWdGKh8Ts4EFT3l_XhOfuy8xbuTxeZXSHGPATI2vKlJLKcFGxeaEj0mmJx35dTEuQFv4l30jYmhgAtoV2gBU9_hAf16-gwLBKyVpoSQS2MgGEwVKg5DyS_Isxl8xpeP8ZJ8e3_z9fpje_vlw6fr3W1rOtGXdhTAAKTiSpp5AqTM8F4YK3qjjBR06KRUhloL3LJpYHLoVY9jzwWTMNZvXpK3W90lxe9HzEUfXDbofW0uHrPmbBg5l4qJir7Z0D141C7MsSQwK653wzpp2vWyUlf_oOqyeHB1Hji7ev-XgG0Ck2LOCWe9JHeAdNKM6tVGvdmoq416tVGPVfP6sevjdED7R_HbtwrwDcj1Kewx6ft4TKFO8j9VfwLBaqdW</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Yagi, Toshinari</creator><creator>Fujiishi, Koto</creator><creator>Hasegawa, Akiko</creator><creator>Otsuka, Tomoyuki</creator><creator>Yoshinami, Tetsuhiro</creator><creator>Nishio, Minako</creator><creator>Fujisawa, Fumie</creator><creator>Sugimoto, Naotoshi</creator><creator>Imamura, Fumio</creator><general>Springer Japan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients</title><author>Yagi, Toshinari ; Fujiishi, Koto ; Hasegawa, Akiko ; Otsuka, Tomoyuki ; Yoshinami, Tetsuhiro ; Nishio, Minako ; Fujisawa, Fumie ; Sugimoto, Naotoshi ; Imamura, Fumio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-93a1aa68286cfbae01c253cd35c8c63074668c0dda2d1b7167585e952316a9303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aldehyde Dehydrogenase, Mitochondrial - genetics</topic><topic>Aldehydes</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Asian People - genetics</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breath Tests</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Dehydrogenation</topic><topic>Enzymes</topic><topic>Ethanol - adverse effects</topic><topic>Ethanol - analysis</topic><topic>Female</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - genetics</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Paclitaxel - adverse effects</topic><topic>Paclitaxel - chemistry</topic><topic>Paclitaxel - therapeutic use</topic><topic>Physiological aspects</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yagi, Toshinari</creatorcontrib><creatorcontrib>Fujiishi, Koto</creatorcontrib><creatorcontrib>Hasegawa, Akiko</creatorcontrib><creatorcontrib>Otsuka, Tomoyuki</creatorcontrib><creatorcontrib>Yoshinami, Tetsuhiro</creatorcontrib><creatorcontrib>Nishio, Minako</creatorcontrib><creatorcontrib>Fujisawa, Fumie</creatorcontrib><creatorcontrib>Sugimoto, Naotoshi</creatorcontrib><creatorcontrib>Imamura, Fumio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yagi, Toshinari</au><au>Fujiishi, Koto</au><au>Hasegawa, Akiko</au><au>Otsuka, Tomoyuki</au><au>Yoshinami, Tetsuhiro</au><au>Nishio, Minako</au><au>Fujisawa, Fumie</au><au>Sugimoto, Naotoshi</au><au>Imamura, Fumio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients</atitle><jtitle>Breast cancer (Tokyo, Japan)</jtitle><stitle>Breast Cancer</stitle><addtitle>Breast Cancer</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>26</volume><issue>2</issue><spage>229</spage><epage>234</epage><pages>229-234</pages><issn>1340-6868</issn><issn>1880-4233</issn><eissn>1880-4233</eissn><abstract>Background
Paclitaxel (PTX) is an essential anticancer drug used to treat breast cancer. Because it contains alcohol as a solvent, it is contraindicated in many Japanese breast cancer patients when they are suspected of alcohol intolerance. Aldehyde dehydrogenase 2 (ALDH2) is one of several enzymes that catalyzes dehydrogenation of aldehydes, and plays an important role in ethanol metabolism. Deficiency of this isozyme is believed to be responsible for facial flushing and other unpleasant symptoms following ethanol intake. In this study, we examined the safety of PTX for patients with the ALDH2 GA genotype.
Methods
We performed ALDH2 genotyping on 25 patients with various cancers who were suspected to be intolerant to alcohol based on an interview using a simple question. Ten patients with the ALDH2 GA genotype, including 5 breast cancer patients, underwent chemotherapy containing PTX up to 100 mg/m
2
(range 80–100 mg/m
2
), and were questioned about 16 alcohol-related symptoms at 11 timepoints to evaluate sensitivity to alcohol.
Results
All patients completed the first course of planned chemotherapy with either no or grade 1 alcohol-related symptoms.
Conclusions
Our study suggests that PTX up to 100 mg/m
2
can be used safely for patients with the ALDH2 GA genotype. To confirm the necessity of a genotyping test for ALDH2, further studies evaluating alcohol sensitivity in response to PTX among patients with the ALDH2 AA genotype are required.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>30350259</pmid><doi>10.1007/s12282-018-0918-9</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-6868 |
| ispartof | Breast cancer (Tokyo, Japan), 2019-03, Vol.26 (2), p.229-234 |
| issn | 1340-6868 1880-4233 1880-4233 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179226813 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aldehyde Dehydrogenase, Mitochondrial - genetics Aldehydes Antineoplastic Agents - adverse effects Antineoplastic Agents - chemistry Asian People - genetics Breast cancer Breast Neoplasms - genetics Breath Tests Cancer Cancer patients Cancer Research Care and treatment Chemotherapy Dehydrogenation Enzymes Ethanol - adverse effects Ethanol - analysis Female Genetic aspects Humans Medicine Medicine & Public Health Middle Aged Neoplasms - drug therapy Neoplasms - genetics Oncology Original Article Paclitaxel - adverse effects Paclitaxel - chemistry Paclitaxel - therapeutic use Physiological aspects Surgery Surgical Oncology |
| title | Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A19%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aldehyde%20dehydrogenase%202%20genotype%20in%20tolerability%20of%20alcohol%20contained%20in%20paclitaxel%20in%20Japanese%20breast%20cancer%20patients&rft.jtitle=Breast%20cancer%20(Tokyo,%20Japan)&rft.au=Yagi,%20Toshinari&rft.date=2019-03-01&rft.volume=26&rft.issue=2&rft.spage=229&rft.epage=234&rft.pages=229-234&rft.issn=1340-6868&rft.eissn=1880-4233&rft_id=info:doi/10.1007/s12282-018-0918-9&rft_dat=%3Cgale_proqu%3EA712280456%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179226813&rft_id=info:pmid/30350259&rft_galeid=A712280456&rfr_iscdi=true |